KR102871719B1 - 숙시네이트 프로드러그, 숙시네이트 프로드러그를 포함하는 조성물들 및 그것의 용도들 - Google Patents

숙시네이트 프로드러그, 숙시네이트 프로드러그를 포함하는 조성물들 및 그것의 용도들

Info

Publication number
KR102871719B1
KR102871719B1 KR1020227002009A KR20227002009A KR102871719B1 KR 102871719 B1 KR102871719 B1 KR 102871719B1 KR 1020227002009 A KR1020227002009 A KR 1020227002009A KR 20227002009 A KR20227002009 A KR 20227002009A KR 102871719 B1 KR102871719 B1 KR 102871719B1
Authority
KR
South Korea
Prior art keywords
compound
mitochondrial
isolated compound
complex
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227002009A
Other languages
English (en)
Korean (ko)
Other versions
KR20220024780A (ko
Inventor
매그너스 요아킴 한슨
알바 그뢴버그
맷츠 에스킬 엘머
마크 리차드 파머리
스티븐 제임스 모스
리 로버트 웹스터
매튜 앨런 그레고리
Original Assignee
앱리바 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앱리바 에이비 filed Critical 앱리바 에이비
Publication of KR20220024780A publication Critical patent/KR20220024780A/ko
Application granted granted Critical
Publication of KR102871719B1 publication Critical patent/KR102871719B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020227002009A 2019-06-19 2020-06-18 숙시네이트 프로드러그, 숙시네이트 프로드러그를 포함하는 조성물들 및 그것의 용도들 Active KR102871719B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970384 2019-06-19
DKPA201970384 2019-06-19
PCT/EP2020/066923 WO2020254484A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Publications (2)

Publication Number Publication Date
KR20220024780A KR20220024780A (ko) 2022-03-03
KR102871719B1 true KR102871719B1 (ko) 2025-10-15

Family

ID=71130953

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002009A Active KR102871719B1 (ko) 2019-06-19 2020-06-18 숙시네이트 프로드러그, 숙시네이트 프로드러그를 포함하는 조성물들 및 그것의 용도들

Country Status (10)

Country Link
US (2) US11565998B2 (enExample)
EP (2) EP3986862B1 (enExample)
JP (2) JP7699551B2 (enExample)
KR (1) KR102871719B1 (enExample)
CN (1) CN113993842B (enExample)
CA (1) CA3143112A1 (enExample)
IL (1) IL288990B2 (enExample)
MA (1) MA56506A (enExample)
MX (1) MX2021015137A (enExample)
WO (1) WO2020254484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
PT3129016T (pt) 2014-04-08 2018-10-01 Neurovive Pharmaceutical Ab Compostos novos
CA2944575A1 (en) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Aug. 2005, p. 4503-4509, 1부.*

Also Published As

Publication number Publication date
MX2021015137A (es) 2022-01-18
US20230033294A1 (en) 2023-02-02
WO2020254484A1 (en) 2020-12-24
US20220162162A1 (en) 2022-05-26
EP4360708A2 (en) 2024-05-01
JP2025004155A (ja) 2025-01-14
EP3986862A1 (en) 2022-04-27
MA56506A (fr) 2022-04-27
CN113993842A (zh) 2022-01-28
IL288990A (en) 2022-02-01
EP3986862C0 (en) 2024-01-24
US11565998B2 (en) 2023-01-31
CA3143112A1 (en) 2020-12-24
US12162824B2 (en) 2024-12-10
JP7699551B2 (ja) 2025-06-27
CN113993842B (zh) 2024-07-16
JP2022538009A (ja) 2022-08-31
KR20220024780A (ko) 2022-03-03
IL288990B2 (en) 2025-09-01
BR112021024510A2 (pt) 2022-01-18
EP3986862B1 (en) 2024-01-24
IL288990B1 (en) 2025-05-01
AU2020298031A1 (en) 2022-02-03
EP4360708A3 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
US9439915B2 (en) Activated nitric oxide donors and methods of making and using thereof
US20030220301A1 (en) Metformin salts of lipophilic acids
KR20220116539A (ko) 프테로스틸벤의 공결정 및 이를 포함하는 조성물
US12162824B2 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
KR20210070978A (ko) 화합물 및 이의 용도
KR20240037940A (ko) Ppar 작용제 화합물의 사용 방법 및 이의 약학 조성물
AU2020298031B2 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
US20240033234A1 (en) Therapeutic compounds, formulations, and use thereof
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
EA045539B1 (ru) Сукцинатное пролекарство, композиции, содержащие сукцинатное пролекарство, и их применение
BR112021024510B1 (pt) 3-[(2-acetilaminoetiltio)carbonil]propionato de metila isolado, cosmecêutico, nutricosméticos, bebida energética, e, composição farmacêutica
US9751840B2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
WO2017060418A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
JP5376786B2 (ja) 神経細胞賦活組成物
US11958857B1 (en) 5-(1H-indol-3-yl)-1,3-substitutedpyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione as anticancer agents
CN105367622B (zh) 一种阿加曲班化合物
WO2011162633A1 (ru) Мягкие катионные митохондриальные разобщители
JP2010500387A (ja) 結晶形態のエポチロンｂおよび医薬組成物における使用
EP4561551A1 (en) Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
KR100923434B1 (ko) 시부트라민 티옥트산염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2017060422A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601